Showing 100,781 - 100,800 results of 105,158 for search '(( 2 de decrease ) OR ( 5 ((((fold decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.86s Refine Results
  1. 100781

    Table_2_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  2. 100782

    Table_3_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  3. 100783

    Table_1_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  4. 100784

    Table_4_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  5. 100785

    Silver Nanocubes Coated in Ceria: Core/Shell Size Effects on Light-Induced Charge Transfer by Devin B. O’Neill (8162448)

    Published 2019
    “…This is fully explainable by CT from silver to the 4-MBA LUMO, with the increase for excitation wavelengths that exceed the Ag/4-MBA LUMO gap of 2.28 eV (543 nm). A second general trend observed is an increase in CT yield with ceria shell thickness, which is assigned to relaxation of the excited electron further into the ceria conduction band, potentially producing defects.…”
  6. 100786

    Table_4_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  7. 100787

    Table_3_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  8. 100788

    Table_2_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  9. 100789

    Table_1_Retrospective investigation of the origin and epidemiology of the dengue outbreak in Yunnan, China from 2017 to 2018.DOCX by Liang Cao (135383)

    Published 2023
    “…<p>Since 2013, a dengue epidemic has broken out in Yunnan, China and neighboring countries. …”
  10. 100790

    Supplementary Material for: Prediction of Therapeutic Response Using Contrast-Enhanced Ultrasound in Japanese Patients Treated with Atezolizumab and Bevacizumab for Unresectable He... by Takada H. (11871941)

    Published 2022
    “…Cases without decreased blood flow in TIC analysis (<i>n</i> = 10) had more cases with PD compared with cases with decreased blood flow (60 vs. 0%, <i>p</i> = 0.001). …”
  11. 100791

    Table_1_Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.docx by Johanna Matull (18767917)

    Published 2024
    “…GNAQ and GNA11 mutations were common in uveal melanomas, while MAP-Kinase mutations were frequent in non-uveal melanomas with NF1, BRAF V600 and NRAS Q61 mutations occurring in decreasing frequency, consistent with a strong UV association. …”
  12. 100792

    Data_Sheet_1_Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung... by Xia Luo (169127)

    Published 2022
    “…When compared with lorlatinib and alectinib, ensartinib was associated with a lower QALY and decreased total costs; the ICERs for lorlatinib and alectinib were $934,101/ QALY and $164,888/ QALY, respectively.…”
  13. 100793
  14. 100794
  15. 100795
  16. 100796
  17. 100797
  18. 100798
  19. 100799
  20. 100800